98%
921
2 minutes
20
Mechanism-based inactivation (MBI) refers to the metabolic bioactivation of a xenobiotic by cytochrome P450s to a highly reactive intermediate which subsequently binds to the enzyme and leads to the quasi-irreversible or irreversible inhibition. Xenobiotics, mainly drugs with specific functional units, are the major sources of MBI. Two possible consequences of MBI by medicinal compounds are drug-drug interaction and severe toxicity that are observed and highlighted by clinical experiments. Today almost all of these latent functional groups (e.g., thiophene, furan, alkylamines, etc.) are known, and their features and mechanisms of action, owing to the vast experimental and theoretical studies, are determined. In the past decade, molecular modeling techniques, mostly density functional theory, have revealed the most feasible mechanism that a drug undergoes by P450 enzymes to generate a highly reactive intermediate. In this review, we provide a comprehensive and detailed picture of computational advances toward the elucidation of the activation mechanisms of various known groups with MBI activity. To this aim, we briefly describe the computational concepts to carry out and analyze the mechanistic investigations, and then, we summarize the studies on compounds with known inhibition activity including thiophene, furan, alkylamines, terminal acetylene, etc. This study can be reference literature for both theoretical and experimental (bio)chemists in several different fields including rational drug design, the process of toxicity prevention, and the discovery of novel inhibitors and catalysts.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/acs.chemrestox.0c00483 | DOI Listing |
Sci Transl Med
September 2025
Department of Medicine, Columbia University Irving Medical Center, New York, NY 10032, USA.
Hepatocyte apoptosis is a key feature of metabolic dysfunction-associated steatohepatitis (MASH), but the fate of apoptotic hepatocytes in MASH is poorly understood. Here, we explore the hypotheses that clearance of dead hepatocytes by liver macrophages (efferocytosis) is impaired in MASH because of low expression of the efferocytosis receptor T cell immunoglobulin and mucin domain containing 4 (TIM4; gene ) by MASH liver macrophages, which then drives liver fibrosis in MASH. We show that apoptotic hepatocytes accumulate in human and experimental MASH, using mice fed the fructose-palmitate-cholesterol (FPC) diet or the high-fat, choline-deficient amino acid-defined (HF-CDAA) diet.
View Article and Find Full Text PDFDrug Metab Dispos
August 2025
Pfizer Inc., Pharmacokinetics, Dynamics & Metabolism, Bothell, Washington. Electronic address:
A highly selective tyrosine kinase inhibitor of the human epidermal growth factor receptor 2, tucatinib, has shown remarkable efficacy and safety for treatment of adult patients with advanced, unresectable, or metastatic human epidermal growth factor receptor 2 positive breast cancer, including those with brain metastases. The purpose of this study was to evaluate in vitro the potential to inhibit cytochrome P450 (P450) isoforms for tucatinib. Preliminary in vitro P450 inhibition survey revealed that tucatinib was a weak inhibitor of CYP1A2, CYP2B6, CYP2C19, and CYP2D6 with IC values >20 μM.
View Article and Find Full Text PDFExpert Opin Ther Targets
August 2025
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.
Introduction: Neuroblastoma, a sympathetic nervous system tumor, is known for its remarkable biological heterogeneity. Unlike other neurogenic malignancies driven by mutations, neuroblastoma carries a significant 'transcriptional burden.' Deregulation of transcription unveils in the course of the tumor's natural history, making the advanced stages of the disease intractable.
View Article and Find Full Text PDFAdv Healthc Mater
July 2025
Field of Drug Discovery Research, Faculty of Advanced Life Science, Graduate School of Life Science, Hokkaido University, N21, W11, Kita-ku, Sapporo, 001-0021, Japan.
Pancreatic ductal adenocarcinoma (PDAC) is an increasing incidence and is the deadliest cancer. Most pancreatic cancer patients present with nonspecific symptoms at an advanced disease stage that is not amenable to curative surgery. Therapies by immune checkpoint inhibitors have proven difficult in the patients with PDAC.
View Article and Find Full Text PDFPharmaceuticals (Basel)
June 2025
Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, The State University of New York, Buffalo, NY 14214, USA.
The increasing occurrence of carbapenem resistance (CRAB) has forced clinicians to seek out alternative options with activity against CRAB. CRAB with inactivated PBP7/8 has been shown to result in an increased outer membrane permeability and could serve as a potential new adjuvant target. : Two isogenic clinical isolates of HUMC1 were utilized (WT and HUMC1 ΔPBP7/8).
View Article and Find Full Text PDF